Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More

RATINGS CHANGES

Alexion (ALXN) was upgraded to overweight from equal-weight at Barclays. $155 price target. The company has multiple potential catalysts for 2017, Barclays said. 

Bob Evans (BOBE) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: BOBE.

Delphi (DLPH) was downgraded to underweight from overweight at Morgan Stanley. $59 price target. The company is seeing slower growth and realizing lower margins, given increased competition, Morgan Stanley said. 

Darden Restaurants (DRI) was downgraded to neutral from outperform at Credit Suisse. The valuation is less attractive, based on a $72 price target, Credit Suisse said. 

Greif (GEF) was downgraded to equal-weight from sector weight at Keybanc. $47 price target. Organic sales growth will likely remain weak and currency should be a drag in 2017, Keybanc said. 

Goldman Sachs (GS) was downgraded to neutral at Nomura. The valuation is less attractive, following the recent rally, Nomura said. 

Johnson & Johnson (JNJ) was downgraded to equal-weight from overweight at Barclays. The valuation is less attractive, based on a $125 price target, Barclays said. 

Pfizer (PFE) was upgraded to overweight from equal-weight at Barclays. $38 price target. The company should be able to use foreign cash to boost returns and the oncology business will drive growth, Barclays said. 

Vertex Pharmaceuticals (VRTX) was downgraded to equal-weight from overweight at Barclays $90 price target. The company has an uncertain clinical profile, Barclays said.  

U.S. Steel (X) was upgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: X.

This article was written by a staff member of TheStreet.

More from Stocks

Tesla CEO Elon Musk Is a Rock Star: Kiss Icon Gene Simmons

Tesla CEO Elon Musk Is a Rock Star: Kiss Icon Gene Simmons

The Best Investment Advice? Stay Diversified

The Best Investment Advice? Stay Diversified

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Listen: Should You Buy Cisco Now?

Listen: Should You Buy Cisco Now?

Amazon Could Devastate Walgreens and Rite Aid by Getting Into Pharmacy Business

Amazon Could Devastate Walgreens and Rite Aid by Getting Into Pharmacy Business